These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11176025)

  • 1. The disconnect between the HCFA and the FDA.
    Firth BG
    J Invasive Cardiol; 2001 Feb; 13(2):136-8; discussion 158-70. PubMed ID: 11176025
    [No Abstract]   [Full Text] [Related]  

  • 2. Satisfying the requirements of the Food and Drug Administration and Centers for Medicare and Medicare Services.
    Smith JJ; Henderson JA
    J Am Coll Radiol; 2008 Mar; 5(3):189-92. PubMed ID: 18312966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential legal barriers to increasing CMS/FDA collaboration: the law of trade secrets and related considerations.
    Wang SS; Smith JJ
    Food Drug Law J; 2003; 58(4):613-27. PubMed ID: 15027453
    [No Abstract]   [Full Text] [Related]  

  • 4. Medicare program; withdrawal of coverage of certain investigational intraocular lenses.--HCFA. Final notice.
    Fed Regist; 1991 Apr; 56(83):19874-9. PubMed ID: 10170736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The blind hog and the acorn: Medicare coverage for investigational devices.
    Betz R
    J Healthc Resour Manag; 1995 Mar; 13(3):31-2. PubMed ID: 10154864
    [No Abstract]   [Full Text] [Related]  

  • 6. New obstacles in the path of marketing new medical devices.
    Bucci VA; Reiss JB; Hall NC
    J Health Care Technol; 1985; 2(2):81-96. PubMed ID: 10300491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCFA urged to speed approval of technologies.
    Firshein J
    Hospitals; 1986 Jul; 60(14):67. PubMed ID: 3522405
    [No Abstract]   [Full Text] [Related]  

  • 8. Medical devices; revocation of cardiac pacemaker registry. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Nov; 64(226):66105-6. PubMed ID: 11010690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologics products; establishment registration and product listing for manufacturers of human blood and blood products; amendment to exempt certain transfusion services from registration--FDA. Final rule.
    Fed Regist; 1984 Aug; 49(171):34448-51. PubMed ID: 10299643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using the MADIT II criteria for implantable cardioverter defibrillators-what is the role of the Food and Drug Administration approval?
    Barold HS
    Card Electrophysiol Rev; 2003 Dec; 7(4):443-6. PubMed ID: 15071272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Median approval times for class III medical devices have been well above statutory deadlines set for FDA and CMS.
    Zinn AM; Allen JC; Hacker CS
    Health Aff (Millwood); 2012 Oct; 31(10):2304-13. PubMed ID: 23048112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dollars and stents: is reimbursement floating out of reach?
    Rohland P
    J Cardiovasc Manag; 1999; 10(6):16-7. PubMed ID: 10662365
    [No Abstract]   [Full Text] [Related]  

  • 13. Miracles in the making.
    Wagner L
    Provider; 2003 Mar; 29(3):22-6, 28, 31-6. PubMed ID: 12666330
    [No Abstract]   [Full Text] [Related]  

  • 14. Coordination of federal regulation and payment for new diagnostic tests: a proposed new approach.
    Schoonmaker M; Bagley GP; Scanlan MK
    Food Drug Law J; 2002; 57(2):195-204. PubMed ID: 12436983
    [No Abstract]   [Full Text] [Related]  

  • 15. Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain.
    Chambers JD; May KE; Neumann PJ
    Health Aff (Millwood); 2013 Jun; 32(6):1109-15. PubMed ID: 23733986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Former FDA Commissioner heads CMS.
    FDA Consum; 2004; 38(3):6. PubMed ID: 15218834
    [No Abstract]   [Full Text] [Related]  

  • 17. Medicare program; removal of the requirements for the cardiac pacemaker registry. Health Care Financing Administration, HHS. Final rule.
    Fed Regist; 2000 Oct; 65(203):62645-6. PubMed ID: 11503683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future state of FDA-CMS parallel reviews.
    Messner DA; Tunis SR
    Clin Pharmacol Ther; 2012 Mar; 91(3):383-5. PubMed ID: 22343814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small miracles: point-of-care testing.
    Wick JY
    Consult Pharm; 2010 Jul; 25(7):416-8, 425-31. PubMed ID: 20601347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety valve may reduce adverse events during open-heart surgery.
    Ankney RN; Kolff J; Loeffler K
    J Healthc Risk Manag; 1997; 17(2):12-8. PubMed ID: 10173138
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.